STAT Plus: Roche’s Alzheimer’s failure increases tension for Biogen
NATIONAL INSTITUTE ON AGING, NIH
The news is not weighing on Roche's stock, but it is weighing on Biogen, which is betting its future on another beta-amyloid-targeting drug.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario